Impact of 18 F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Frontiers in Medicine

article

Francesco Martucci¹  Mariarosa Pascale²  Maria Carla Valli¹  Gianfranco A. Pesce¹  Patrizia Froesch³  Luca Giovanella⁴  Antonella Richetti¹  Giorgio Treglia⁵ 

[1] Clinic of Radiation Oncology, Oncology Institute of Southern Switzerland;Clinical Trial Unit;Clinic of Medical Oncology, Oncology Institute of Southern Switzerland;Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland;Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne;Health Technology Assessment Unit, Research and Innovation Area

关键词: positron emission tomography/CT;    molecular imaging;    staging;    lung cancer;    small cell lung cancer;   

DOI  :  10.3389/fmed.2019.00336

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Background: Molecular imaging methods are currently used in the management of patients with lung cancer. Compared to non-small cell lung cancer, less data are available about the impact of molecular imaging using fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) in staging patients with small cell lung cancer (SCLC). Performing a systematic review and meta-analysis, we aimed to provide quantitative data about the impact of 18 F-FDG PET/CT in staging SCLC. Methods: A comprehensive literature search of studies on the use of 18 F-FDG PET/CT in patients with SCLC was performed. Three different databases were screened (PubMed/MEDLINE, EMBASE, and Cochrane library databases) until June 2019. Only articles describing the impact of 18 F-FDG PET/CT in staging patients with SCLC were selected. A pooled analysis evaluating the change of binary SCLC staging (limited-stage vs. extensive-stage disease) using 18 F-FDG PET/CT was carried out. Results: Nine articles including 721 patients with SCLC were included in the systematic review. Compared to conventional staging, a superior diagnostic accuracy of 18 F-FDG PET/CT was found. A change of binary SCLC staging using 18 F-FDG PET/CT was demonstrated in 15% (95% confidence interval, 9–21%) of patients with SCLC. Currently, it is not clearly demonstrated that the use of 18 F-FDG PET/CT for staging may improve the survival outcome of patients with SCLC. Conclusions:18 F-FDG PET/CT is a useful molecular imaging method for staging patients with SCLC because it can change the management in a significant number of patients. More large prospective studies and cost-effectiveness analyses on the impact of 18 F-FDG PET/CT in staging patients with SCLC are needed.

【 授权许可】

CC BY